Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
48 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Guillain-Barre Syndrome - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2016, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape. Guillain-Barre syndrome (GBS) is a disorder in which the body's immune system attacks part of the peripheral nervous system. The first symptoms of this disorder include varying degrees of weakness or tingling sensations in the legs. In many instances the symmetrical weakness and abnormal sensations spread to the arms and upper body. These symptoms can increase in intensity until certain muscles cannot be used at all and, when severe, the person is almost totally paralyzed. Risk Factors include influenza virus, mycoplasma pneumonia, Hodgkin's lymphoma and Epstein-Barr virus. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Guillain-Barre Syndrome - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Guillain-Barre Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Guillain-Barre Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Guillain-Barre Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 2 and 3 respectively for Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively for Guillain-Barre Syndrome. Guillain-Barre Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Guillain-Barre Syndrome (Central Nervous System). - The pipeline guide reviews pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Guillain-Barre Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Guillain-Barre Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Guillain-Barre Syndrome (Central Nervous System) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Guillain-Barre Syndrome (Central Nervous System). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Guillain-Barre Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Guillain-Barre Syndrome Overview 6 Therapeutics Development 7 Pipeline Products for Guillain-Barre Syndrome - Overview 7 Pipeline Products for Guillain-Barre Syndrome - Comparative Analysis 8 Guillain-Barre Syndrome - Therapeutics under Development by Companies 9 Guillain-Barre Syndrome - Therapeutics under Investigation by Universities/Institutes 10 Guillain-Barre Syndrome - Pipeline Products Glance 11 Late Stage Products 11 Clinical Stage Products 12 Early Stage Products 13 Guillain-Barre Syndrome - Products under Development by Companies 14 Guillain-Barre Syndrome - Products under Investigation by Universities/Institutes 15 Guillain-Barre Syndrome - Companies Involved in Therapeutics Development 16 Akari Therapeutics, Plc 16 CuraVac, Inc. 17 Hansa Medical AB 18 Regenesance BV 19 Vitality Biopharma Inc 20 Guillain-Barre Syndrome - Therapeutics Assessment 21 Assessment by Monotherapy Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 Coversin - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 immune globulin (human) - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 Recombinant Enzyme to Inhibit Immunoglobulin G for Kidney Transplantation, Central Nervous System and Autoimmune Disorders - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 Small Molecule to Inhibit C6 for Guillain-Barre Syndrome - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 Small Molecules to Agonize CB1 and CB2 for Central Nervous System Disorders - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 Vaccine for Guillain-Barre Syndrome - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Guillain-Barre Syndrome - Dormant Projects 42 Guillain-Barre Syndrome - Product Development Milestones 43 Featured News & Press Releases 43 May 23, 2016: Akari Therapeutics Receives Positive Opinion for Orphan Drug Designation for Coversin in the European Union for Treatment of Guillain-Barre Syndrome 43 May 12, 2016: Akari Therapeutics Announces Receipt of Orphan Drug Designation for Coversin from the U.S. FDA for Treatment of Guillain-Barre Syndrome 43 Jan 29, 2016: Akari Therapeutics Receives Approval From the UK Medicines & Healthcare Products Regulatory Agency for Phase IB Multiple Ascending Dose Trial 44 Jan 05, 2016: Akari Therapeutics Announces Additional Data from Non-Human Primate Safety Study Demonstrating Equivalent Coversin Efficacy in Both Elisa CH50 and Hemolytic SRBC Assays 44 Dec 07, 2015: Akari Therapeutics Announces Update From Non-Human Primate Safety Study at International PNH Interest Group 10th Annual Scientific Meeting 45 Appendix 47 Methodology 47 Coverage 47 Secondary Research 47 Primary Research 47 Expert Panel Validation 47 Contact Us 47 Disclaimer 48
List of Tables
Number of Products under Development for Guillain-Barre Syndrome, H2 2016 7 Number of Products under Development for Guillain-Barre Syndrome - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Late Stage Development, H2 2016 11 Comparative Analysis by Clinical Stage Development, H2 2016 12 Comparative Analysis by Early Stage Development, H2 2016 13 Products under Development by Companies, H2 2016 14 Products under Investigation by Universities/Institutes, H2 2016 15 Guillain-Barre Syndrome - Pipeline by Akari Therapeutics, Plc, H2 2016 16 Guillain-Barre Syndrome - Pipeline by CuraVac, Inc., H2 2016 17 Guillain-Barre Syndrome - Pipeline by Hansa Medical AB, H2 2016 18 Guillain-Barre Syndrome - Pipeline by Regenesance BV, H2 2016 19 Guillain-Barre Syndrome - Pipeline by Vitality Biopharma Inc, H2 2016 20 Assessment by Monotherapy Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Guillain-Barre Syndrome - Dormant Projects, H2 2016 42
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.